Dr. Szablewski is a CDC Epidemic Intelligence Service officer at the Georgia Department of Public Health, Atlanta, GA. Her primary interest is acute disease epidemiology.

References


Address for correspondence: Kelly A. Shaw, Virginia Department of Health, 109 Governor St, Office 531, Richmond, VA 23219, USA; email: nrb7@cdc.gov

Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy

Chloé Medrano, François Vergez, Catherine Mengelle, Stanislas Faguer, Nassim Kamar, Arnaud Del Bello

Author affiliations: Hôpital Rangueil, Toulouse, France (C. Medrano, S. Faguer, N. Kamar, A. Del Bello); Université Paul Sabatier, Toulouse (C. Medrano, F. Vergez, S. Faguer, N. Kamar, A. Del Bello); Hôpital de Toulouse, Toulouse (F. Vergez, C. Mengelle); Hôpital Purpan, Toulouse (C. Mengelle, N. Kamar, A. Del Bello)

DOI: https://doi.org/10.3201/eid2511.190705

Antibodies against PD1 have been used to treat progressive multifocal leukoencephalopathy (PML), a rare brain disease caused by JC virus. We used these antibodies (nivolumab) to treat PML in 3 kidney transplant recipients. All died within 8 weeks of diagnosis. Hence, nivolumab did not improve PML outcome after solid organ transplantation.

The role of T-cell exhaustion in the development of progressive multifocal leukoencephalopathy (PML), a rare brain disease caused by JC virus, has prompted clinicians to use immune checkpoint inhibitor molecules to treat JC virus–infected patients. Recently, Cortese et al. (1) used antibodies against PD1 to treat PML in 8 patients (6 with a history of blood disorders and 2 with HIV infection). They noted improvement or stabilization of symptoms for 5 patients but no benefit for the others.

Since 2017, we have treated PML in 3 kidney transplant recipients with a definitive diagnosis, according to the American Academy of Neurology (https://www.aan.com) consensus, made 5 (range 2–17) years after transplantation. We have compiled clinical and radiologic findings for these patients (Appendix Figures 1–3, https://wwwnc.cdc.gov/EID/article/25/11/19-0705-App1.pdf). Since transplantation, the patients had been receiving mycophenolic acid and steroids with either belatacept (n = 1) or tacrolimus (n = 2). At PML diagnosis, immunosuppressants were immediately withdrawn, and nivolumab (antibodies against PD1) was given at a dose of 3 mg/kg every 15 days (2 injections for 2 patients and 3 injections for 1) (Table). For the patient who had received belatacept, we performed 3 apheresis sessions to remove the drug before nivolumab initiation. All patients died within the first 8 weeks after PML diagnosis because of rapid progression of neurologic symptoms.
Magnetic resonance imaging was performed before each injection and a few days before death, but images showed no signs of immune reconstitution inflammatory syndrome. Conversely, images did show progression of PML features. As expected, the percentage of T cells expressing PD1, which was assessed for 2 patients, dramatically decreased after receipt of nivolumab (Appendix Figure 4), whereas other inhibitory receptors tested (2b4 and CD160) remained stable or increased. In addition, functional analysis showed a reduction of cytokine production by CD4+ and CD8+ T cells and an improvement of cytotoxic ability, a phenotype compatible with more terminally differentiated exhausted cells, which are less likely to respond to anti-PD1 immune checkpoint inhibitors (2).

Research has suggested that PML could occur at any time after transplantation (3), even several years after engraftment, which was the case for the 3 patients reported here. As opposed to the results reported by Cortese et al. (1), the outcomes for the 3 patients we report, who received nivolumab, was very bad and in line with the PML outcomes usually reported after solid-organ transplant patients (i.e., median survival time <6 months) (3). The difference between the patients reported by Cortese et al. and the patients that we report is probably due to immunosuppressive agents (calcineurin inhibitors or co-stimulation blockers) that can lead to persistent T-cell dysfunction, despite withdrawal of these treatments, resulting in refractory T-cell dysfunction after use of anti-PD1 blockers, as reported in ex vivo experiments (4). This hypothesis is supported by the absence of kidney rejection in 2 of the 3 patients. Of note, all 5 patients reported by Cortese et al. (1) for whom anti-PD1 blockers were efficient were not receiving immunosuppressive therapy at PML diagnosis. Moreover, the 3 patients reported here had profound lymphopenia at diagnosis, which for 2 patients did not improve after receipt of nivolumab (Table). Although there is no established relationship between the severity of lymphopenia and the response to anti-PD1, the 3 patients with unfavorable outcomes reported by Cortese et al. (1) also had severe lymphopenia. This finding suggests that immunotherapies can be ineffective in patients with severe lymphopenia. The use of ex vivo expanded, BK virus–specific T cells (5) should be tested in this setting. For the kidney transplant patients with PML reported here, use of nivolumab, associated with immunosuppressive therapy withdrawal, did not restore efficient immune response and did not improve the outcomes.

### About the Author
Dr. Medrano is a nephrologist who works in the nephrology and organ transplant department at the Hôpital Rangueil in Toulouse, France, and specializes in intensive care therapy.

### References
Endemicity of Yaws and Seroprevalence of *Treponema pallidum* Antibodies in Nonhuman Primates, Kenya


Author affiliations: Smithsonian Conservation Biology Institute, Washington DC, USA (D.M. Zimmerman, E.H. Hardgrove, M.E. von Fricken); George Mason University, Fairfax, Virginia, USA (D.M. Zimmerman, M.E. von Fricken); Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA (E.H. Hardgrove); Institute of Primate Research, Nairobi, Kenya (J. Kamau, D. Chai, S. Mutura, F. Hussein, P. Ambala); International Livestock Research Institute, Nairobi (V. Kivali); Mpala Research Centre and Wildlife Foundation, Nanyuki, Kenya (A. Surmat); Kenya Wildlife Service, Nairobi (J.G. Maina); German Primate Center, Goettingen, Germany (S. Knauf)

DOI: https://doi.org/10.3201/eid2511.190716

Human yaws has historically been endemic to Kenya, but current epidemiologic data are lacking. We report seroprevalence for *Treponema pallidum* antibodies in olive baboons (*Papio anubis*) and vervet monkeys (*Chlorocebus pygerythrus*) in Laikipia County, Kenya. Our results suggest endemicity of the yaws bacterium in monkeys, posing a possible zoonotic threat to humans.

Yaws is a disease caused by the bacterium *Treponema pallidum* subsp. *pertenue*, which is believed to be an exclusively human pathogen (1). However, this bacterium has recently been identified in African nonhuman primates (NHPs) (2), raising concerns about a possible zoonotic reservoir for human infection. Kenya is 1 of 76 countries that the World Health Organization categorizes as previously endemic for yaws, but no current data support its presence or absence (http://apps.who.int/gho/data/node.main.NTDYAWSEND). However, sustainable yaws eradication will rely on information about transmission dynamics and potential links between human and NHP *T. pallidum* strains (3).

In the early 1960s, Fribourg-Blanc and Mollaret tested 150 serum samples from wild-caught baboons (*Papio* sp.) from Guinea and Kenya (4). Although 72 (65%) of 111 serum samples from Guinea were positive for *T. pallidum* antibodies, none of the samples from Kenya were positive. In subsequent years, an additional 276 serum samples from baboons in Kenya supported the absence of *T. pallidum* infection. However, a more recent study of baboon samples collected during 1977–1994 in Kenya reported serologic evidence of *T. pallidum* infection in Nanyuki, Laikipia County (prevalence 57.5%) (5). For our study, we hypothesized that 39 years after the first samples were positive for antibodies against *T. pallidum* in Nanyuki (5), infection is still present in the NHP population.

All animal protocols were approved by the Kenya Wildlife Service (permit #4004), the Institute of Primate Research Scientific and Ethics Review Committee, and the Smithsonian Institution Animal Use and Care Committee. In October 2016, we sampled 65 olive baboons (*Papio anubis*) and 2 vervet monkeys (*Chlorocebus pygerythrus*) at sites surrounding the Mpala Research Centre in Laikipia County, Kenya. We performed a preliminary serologic screening by using the immunochromatographic Dual Path Platform (DPP) HIV-Syphilis Assay (Chembio Diagnostic Systems, Inc., http://chembio.com) according to the manufacturer guidelines. This syphilis (*T. pallidum*) assay is a useful screening tool because antibodies against *Treponema* subspecies are cross-reactive (6). We tested 67 samples with the DPP assay; 49 were positive and 18 negative.

However, because this test is not certified for use with NHPs, we subsequently confirmed results by using the *T. pallidum* Particle Agglutination Assay (TPPA) (SERODIA TPPA, https://www.fujirebio-us.com), which has been validated for use in baboons (7). Of the 52 samples tested with the TPPA assay, there were 33 positive, 6 negative, and 13 inconclusive results. Inconclusive TPPA results indicate non specific antibodies reacting with nonsensitized particles. Because of limited sample material, we were unable to perform repeated testing with a preabsorption step to remove all nonspecific binding antibodies (as described in the assay manual) and therefore excluded the inconclusive TPPA results from our analysis.
Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy

Appendix

Appendix Figure 1. Clinical course of patient 1. An 81-year-old man had undergone a kidney transplantation in 2012 because of end-stage renal disease related to nephroangiosclerosis. He was given induction therapy by basiliximab followed by a triple immunosuppressive regimen including tacrolimus, mycophenolate mofetil, and prednisone. No acute rejection occurred after transplantation. Five years after kidney transplantation, the patient presented with behavioral disorders and confusion, without fever. At admission, brain-MRI showed several bilateral hyperintense lesions, involving left frontal and right parietal lobe. The diagnosis of PML was confirmed by the detection of JCV DNA in CSF (3.5
log-copies/mL). At day 11, because of worsening of neurologic symptoms (patient unable to sit, psychomotor retardation and somnolence), nivolumab was initiated, and repeated 2 weeks later. One month after the first symptoms, MRI sequences showed several bilateral confluent hyperintense lesions, extended to both frontal lobes, and right parietal lobe without evidence of an inflammatory reaction with edema, mass effect, or gadolinium enhancement suggesting the occurrence of immune reconstitution inflammatory syndrom. The patient became bed bound, felt into coma and died roughly 1 month and a half after admission.

Appendix Figure 2. Clinical course of patient 2. A 77-year-old Caucasian man had undergone a kidney transplantation in 2015 because of nephroangiosclerosis and diabetic nephropathy. No induction therapy was given. Maintenance immunosuppression included tacrolimus, MMF, and prednisolone. One year after transplantation, the patient was converted from tacrolimus to belatacept because of biopsy-proven calcineurin inhibitors nephrotoxicity. At conversion, serum creatinine level was at 33 mg/L. Two years after transplantation (one year after belatacept initiation), the patient presented with profound weakness. At admission, brain FLAIR-MRI sequences revealed bilateral hyperintense lesions in both frontal lobes. The diagnosis of PML was confirmed by the detection of JCV DNA in CSF (2.9 log-copies/mL). Belatacept and MMF were stopped immediately after the diagnosis. In addition, the patient had undergone three sessions of double filtration plasmapheresis (DFPP) to eliminate rapidly belatacept. Immediately after the 3 sessions of DFPP, nivolumab was started (3mg/kg each 15 days). Gamma-
interferon (Intravenous perfusion of Imukin, 100 µg) was added to the second and third injection of nivolumab because of neurologic symptoms deterioration (somnolence, bed-ridden). The second and third MRI showed extension of lesions, without signs of IRIS. The patient died 1 month and half after admission.

Appendix Figure 3. Clinical course of patient 3. A 67-years-old woman had undergone a kidney transplantation in 2007 due to interstitial nephropathy. She was given induction therapy by basiliximab, followed by a triple immunosuppressive therapy including belatacept, MMF, and prednisone. Eleven years after transplantation, belatacept was replaced by tacrolimus, for patient personal suitability. The postransplantation period was uneventful and no acute rejection occurred. Two months after the switch, the patient was admitted for left hemiparesis worsening for the past month. At admission, brain MRI showed PML-compatible bilateral lesions, with hyperintense lesions in corpus callusum in FLAIR sequences. The diagnosis of PML was confirmed by the detection of JCV DNA in CSF (2.9 log-copies/mL). Tacrolimus and MMF were stopped immediately after the diagnosis. Prednisolone was maintained, and mirtazapine was added (15mg/d). Nivolumab (3mg/kg) was started immediately. Because of rapid neurologic symptoms impairment 1 week after the first injection (bed-ridden, somnolence), the patient was given a second injection of nivolumab (3 mg/kg). A brain MRI performed 1 week after the second injection of nivolumab, confirmed the PML progression without argument for IRIS. The patient presented went into coma and died 4 weeks after admission.
Appendix Figure 4. Expression of surface T cells inhibitory molecules in Patient 2 and 3 at diagnosis and after nivolumab injection. Phenotypic analysis of T-cells inhibitory molecules (PD-1, 2B4, CD160) expression in CD4+ (A) and CD8+ (B) cells before and after nivolumab injection in patient 2. Phenotypic analysis of T-cells inhibitory molecules (PD-1/2b4/CD160) in CD4+ (C) and CD8+ (D) cells before and after nivolumab injection in patient 3. In vitro CD4+ (E) and CD8+ (F) T cells production of TNFα, IL-2, IFNγ, Granzyme B (GZB) and IL-17, after unspecific stimulation with PMA/ionomycin, before and after nivolumab injection in patient 3. 50 µl of fresh heparinized blood were incubated for 3h at 37°C, 5% CO2 in a Duractive 1 tube (Beckman Coulter), containing a fixed amount of PMA and Ionomycin. Fixation,
permeabilization and intracellular stainings were performed with the Perfix NC kit and the Duraclone IFT activation kit (Beckman Coulter), according to the manufacturer’s instructions. Following the procedure, cells were immediately analyzed by flow cytometry.